Literature DB >> 17323790

Considerable interindividual variation in the pharmacokinetics of tolperisone HCl.

J W Bae1, M J Kim, Y S Park, C S Myung, C G Jang, S Y Lee.   

Abstract

OBJECTIVE: The aim of this study was to determine the pharmacokinetic profiles of oral tolperisone hydrochloride in healthy volunteers.
METHODS: After the oral administration of tolperisone hydrochloride, the plasma concentrations of tolperisone were measured in 15 healthy male Korean volunteers. The tolperisone concentration was determined using high-performance liquid chromatography with a C18 reverse-phase column.
RESULTS: Very large interindividual differences in the AUC and Cmax were detected after oral tolperisone HCl. The AUC0-infinity, varied from 125.9-1,241.3 ng/ml x h, and the Cmax varied from 64.2 and 784.9 ng/ml. The tmax of tolperisone was 0.90 +/- 0.31 h and the mean half-life was 1.00 +/- 0.28 h.
CONCLUSION: These results suggest that the pharmacological effect of oral tolperisone HCl varies between individuals, and the oral tolperisone HCl dose might need to be individualized.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17323790     DOI: 10.5414/cpp45110

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  3 in total

1.  Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers.

Authors:  M Pawlowska; M Bogiel; J Duda; E Sieradzki
Journal:  Eur J Clin Pharmacol       Date:  2015-05-09       Impact factor: 2.953

Review 2.  Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects.

Authors:  Stefan Quasthoff; Claudia Möckel; Walter Zieglgänsberger; Wolfgang Schreibmayer
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

3.  Classification of drugs based on properties of sodium channel inhibition: a comparative automated patch-clamp study.

Authors:  Nora Lenkey; Robert Karoly; Peter Lukacs; E Sylvester Vizi; Morten Sunesen; Laszlo Fodor; Arpad Mike
Journal:  PLoS One       Date:  2010-12-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.